全文获取类型
收费全文 | 5191篇 |
免费 | 233篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 135篇 |
妇产科学 | 80篇 |
基础医学 | 696篇 |
口腔科学 | 508篇 |
临床医学 | 335篇 |
内科学 | 1144篇 |
皮肤病学 | 51篇 |
神经病学 | 507篇 |
特种医学 | 176篇 |
外科学 | 659篇 |
综合类 | 35篇 |
一般理论 | 2篇 |
预防医学 | 402篇 |
眼科学 | 55篇 |
药学 | 371篇 |
中国医学 | 30篇 |
肿瘤学 | 208篇 |
出版年
2024年 | 3篇 |
2023年 | 39篇 |
2022年 | 102篇 |
2021年 | 211篇 |
2020年 | 115篇 |
2019年 | 160篇 |
2018年 | 196篇 |
2017年 | 134篇 |
2016年 | 128篇 |
2015年 | 198篇 |
2014年 | 236篇 |
2013年 | 276篇 |
2012年 | 464篇 |
2011年 | 467篇 |
2010年 | 255篇 |
2009年 | 200篇 |
2008年 | 338篇 |
2007年 | 367篇 |
2006年 | 331篇 |
2005年 | 283篇 |
2004年 | 240篇 |
2003年 | 241篇 |
2002年 | 205篇 |
2001年 | 26篇 |
2000年 | 12篇 |
1999年 | 22篇 |
1998年 | 19篇 |
1997年 | 23篇 |
1996年 | 16篇 |
1995年 | 10篇 |
1994年 | 12篇 |
1993年 | 7篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 7篇 |
1988年 | 8篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 10篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1936年 | 2篇 |
1922年 | 2篇 |
排序方式: 共有5449条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献5.
6.
7.
8.
Eduardo Rodrigues‐Pinto Joel Ferreira‐Silva Guilherme Macedo Douglas K. Rex 《Digestive endoscopy》2019,31(5):583-587
Cecal intubation is a critical aspect of effective, complete colonoscopy. Difficult colonoscopy is most often considered as one in which it is challenging or impossible to reach the cecum. It may be a common occurrence due to patient and/or endoscopist factors. Incomplete colonoscopies should be avoided, since patients in this context present an important prevalence of lesions that escape examination. The approach to successful cecal intubation should depend on characterization of the problem as redundant colon or difficult sigmoid colon. Most patients with a prior incomplete colonoscopy can be colonoscoped successfully, if careful attention is paid to technique, using a variety of scopes, colonoscopy methods and additional equipment. Sufficient time should be allotted to make the attempt. 相似文献
9.
Milena Soares Santos Guilherme de Sousa Ribeiro Tainara Queiroz Oliveira Renan Cardoso Nery Santos Edilane Gouveia Kátia Salgado Daniele Takahashi Cleuber Fontes Leila Carvalho Campos Mitermayer Galvão Reis Albert Icksang Ko Joice Neves Reis 《International journal of infectious diseases》2009,13(4):456-461
10.
Paula Vanessa Pedron Oltramari Ricardo de Lima Navarro José Fernando Castanha Henriques Rumio Taga Tania Mary Cestari Guilherme Janson José Mauro Granjeiro 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2007,104(5):e9-16
OBJECTIVE: The objective of this study was to radiographically quantify bone density and bone height preservation in tooth extraction alveolus filled with xenograft. STUDY DESIGN: The maxillary and mandibular fourth deciduous molars and fourth premolars of 6 minipigs were removed. Randomly, in 3 animals the right side was used as the test side and in the other 3 animals the left side was the test side. Intraoral radiographs were performed to compare the condition at the initial time and 3 months later. Measurements of bone height and bone density were performed using KS300 (Zeiss) software. RESULTS: After 3 months, there was a statistically significant smaller bone height loss for the test group. The test group presented a statistically greater bone density immediately after tooth extraction. However, after 3 months there was no statistically significant difference between the groups. CONCLUSIONS: The results suggest that treatment of postextraction alveolus with xenograft can preserve bone height initially but differences in bone density compared to when no xenograft is used are not sustained. 相似文献